{
    "clinical_study": {
        "@rank": "52223", 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine the effect of multiple doses of secretin on autism."
        }, 
        "brief_title": "Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction", 
        "condition": "Autism", 
        "condition_browse": {
            "mesh_term": "Autistic Disorder"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Autism\n\n          -  Gastrointestinal dysfunction"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "59 Months", 
            "minimum_age": "32 Months"
        }, 
        "firstreceived_date": "May 8, 2002", 
        "id_info": {
            "nct_id": "NCT00036231", 
            "org_study_id": "RG1068-03"
        }, 
        "intervention": {
            "intervention_name": "RG1068 (Synthetic Human Secretin)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Secretin"
        }, 
        "lastchanged_date": "November 17, 2005", 
        "link": {
            "url": "http://www.repligen.com"
        }, 
        "official_title": "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy, Safety and Tolerability of RG1068 (Synthetic Human Secretin) in Children With Autism and Gastrointestinal Dysfunction", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00036231"
        }, 
        "source": "Repligen Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Repligen Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2005"
    }, 
    "geocoordinates": {}
}